Literature DB >> 19559089

In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles.

Gregory A Dissen1, Alejandro Lomniczi, Tanaya L Neff, Theodore R Hobbs, Steven G Kohama, Christopher D Kroenke, Francesco Galimi, Sergio R Ojeda.   

Abstract

Non-human primates (NHPs) are an invaluable resource for the study of genetic regulation of disease mechanisms. The main disadvantage of using NHPs as a preclinical model of human disease is the difficulty of manipulating the monkey genome using conventional gene modifying strategies. Lentiviruses offer the possibility of circumventing this difficulty because they can infect and transduce either dividing or nondividing cells, without producing an immune response. In addition, lentiviruses can permanently integrate into the genome of host cells, and are able to maintain long-term expression. In this article we describe the lentiviral vectors that we use to both express transgenes and suppress expression of endogenous genes via RNA interference (RNAi) in NHPs. We also discuss the safety features of currently available vectors that are especially important when lentiviral vectors are used in a species as closely related to humans as NHPs. Finally, we describe in detail the lentiviral vector production protocol we use and provide examples of how the vector can be employed to target peripheral tissues and the brain.

Entities:  

Mesh:

Year:  2009        PMID: 19559089      PMCID: PMC2732747          DOI: 10.1016/j.ymeth.2009.06.004

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  48 in total

1.  HIV-1 genome nuclear import is mediated by a central DNA flap.

Authors:  V Zennou; C Petit; D Guetard; U Nerhbass; L Montagnier; P Charneau
Journal:  Cell       Date:  2000-04-14       Impact factor: 41.582

2.  Identification of novel genes coding for small expressed RNAs.

Authors:  M Lagos-Quintana; R Rauhut; W Lendeckel; T Tuschl
Journal:  Science       Date:  2001-10-26       Impact factor: 47.728

3.  VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum.

Authors:  N J DePolo; J D Reed; P L Sheridan; K Townsend; S L Sauter; D J Jolly; T W Dubensky
Journal:  Mol Ther       Date:  2000-09       Impact factor: 11.454

4.  Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells.

Authors:  Neeltje A Kootstra; Carsten Munk; Nina Tonnu; Nathaniel R Landau; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-23       Impact factor: 11.205

5.  A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells.

Authors:  Frank Stegmeier; Guang Hu; Richard J Rickles; Gregory J Hannon; Stephen J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

Review 6.  New insights into the immunology and evolution of HIV.

Authors:  Justin Stebbing; Steve Patterson; Frances Gotch
Journal:  Cell Res       Date:  2003-02       Impact factor: 25.617

7.  Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles.

Authors:  Scott L Butler; Erik P Johnson; Frederic D Bushman
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 8.  Gene transfer into nonhuman primate hematopoietic stem cells: implications for gene therapy.

Authors:  Y Hanazono; K Terao; K Ozawa
Journal:  Stem Cells       Date:  2001       Impact factor: 6.277

9.  Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression.

Authors:  S C Barry; B Harder; M Brzezinski; L Y Flint; J Seppen; W R Osborne
Journal:  Hum Gene Ther       Date:  2001-06-10       Impact factor: 5.695

10.  Development of a novel trans-lentiviral vector that affords predictable safety.

Authors:  X Wu; J K Wakefield; H Liu; H Xiao; R Kralovics; J T Prchal; J C Kappes
Journal:  Mol Ther       Date:  2000-07       Impact factor: 11.454

View more
  22 in total

Review 1.  Optogenetic tools for modulating and probing the epileptic network.

Authors:  Mingrui Zhao; Rose Alleva; Hongtao Ma; Andy G S Daniel; Theodore H Schwartz
Journal:  Epilepsy Res       Date:  2015-06-21       Impact factor: 3.045

2.  Gene networks and the neuroendocrine regulation of puberty.

Authors:  Sergio R Ojeda; Christopher Dubay; Alejandro Lomniczi; Gabi Kaidar; Valerie Matagne; Ursula S Sandau; Gregory A Dissen
Journal:  Mol Cell Endocrinol       Date:  2009-12-22       Impact factor: 4.102

3.  Injection parameters and virus dependent choice of promoters to improve neuron targeting in the nonhuman primate brain.

Authors:  W Lerchner; B Corgiat; V Der Minassian; R C Saunders; B J Richmond
Journal:  Gene Ther       Date:  2014-01-09       Impact factor: 5.250

4.  siRNA Therapeutics for Protein Misfolding Diseases of the Central Nervous System.

Authors:  Mark D Zabel; Luke Mollnow; Heather Bender
Journal:  Methods Mol Biol       Date:  2021

5.  Lipopeptide Delivery of siRNA to the Central Nervous System.

Authors:  Mark D Zabel; Luke Mollnow; Heather Bender
Journal:  Methods Mol Biol       Date:  2019

6.  Choline transporter-like protein 4 (CTL4) links to non-neuronal acetylcholine synthesis.

Authors:  Pingfang Song; Stephen S Rekow; Corey-Ayne Singleton; Harmanjatinder S Sekhon; Gregory A Dissen; Minerva Zhou; Barbara Campling; Jon Lindstrom; Eliot R Spindel
Journal:  J Neurochem       Date:  2013-06-25       Impact factor: 5.372

7.  The application of RNAi-based treatments for inflammatory bowel disease.

Authors:  Morten Tobias Jarlstad Olesen; Borja Ballarín-González; Kenneth Alan Howard
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

8.  Hypothalamic EAP1 (enhanced at puberty 1) is required for menstrual cyclicity in nonhuman primates.

Authors:  Gregory A Dissen; Alejandro Lomniczi; Sabine Heger; Tanaya L Neff; Sergio R Ojeda
Journal:  Endocrinology       Date:  2011-11-29       Impact factor: 4.736

9.  Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures.

Authors:  Bruce Pulford; Natalia Reim; Aimee Bell; Jessica Veatch; Genevieve Forster; Heather Bender; Crystal Meyerett; Scott Hafeman; Brady Michel; Theodore Johnson; A Christy Wyckoff; Gino Miele; Christian Julius; Jan Kranich; Alan Schenkel; Steven Dow; Mark D Zabel
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

10.  Lipopeptide delivery of siRNA to the central nervous system.

Authors:  Mark D Zabel
Journal:  Methods Mol Biol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.